transcodetherapeutics.com (RNAZ) Quarterly EPS earnings growth
TransCode Therapeutics (RNAZ) operates based on a medical trial schedule, ignoring GDP fluctuations. Quarterly EPS dynamics confirm this macro-resilience, with the -40.50 level serving as a critical benchmark. Patents for drug delivery into tumors ensure a high barrier to entry. Operations are further supported by strict compliance with environmental regulations regarding biohazardous waste disposal in laboratory settings.
%20Year-over-year%20earnings%20per%20share%20growth%20for%20the%20last%2012%20months&width=1200&height=400&colorIndex=0&v=mwa76aez.ocr-7cpmfb4&start=20220704&end=20261110&filename=GURU_Markets_-_RNAZ_-_TransCode-Therapeutics_-_Year-over-year-earnings-per-share-growth-for-the-last-12-months "RNAZ: TransCode Quarterly EPS earnings growth 07/04/2022 - 11/10/2026 | 👁️GURU.Markets👁️")
TransCode Therapeutics - analytical breakdowns and key metrics (RNAZ)
- market value and analyst target forecast:
- market capitalization details:
- balance sheet net asset value indicators:
- debt and solvency information:
Total Debt to Equity Ratio TransCode Therapeutics|RNAZ - Long-Term Loans to Capital Ratio|Short-Term Debt to Capital transcodetherapeutics.com|RNAZ - Aggregate Debt Obligations|Debts to Book Capitalization TransCode|RNAZ - Long-Term Debt|Company Short-Term Debt TransCode Therapeutics|Quick Ratio transcodetherapeutics.com
- earnings and valuation multiples indicators:
RNAZ - Net Profit|Expected Profit TransCode Therapeutics|RNAZ - Market Cap to Net Income|Forward P/E Multiple transcodetherapeutics.com|RNAZ - Price to Earnings Adjusted for Growth Rate|Enterprise Value to EBITDA Ratio TransCode|RNAZ - Operating profit EBITDA|Net earnings per share for the last 12 months TransCode Therapeutics|RNAZ - Earnings per share for the last four quarters|Quarterly EPS earnings growth transcodetherapeutics.com|RNAZ - Expected net earnings per share growth this year|Earnings growth forecast for next year TransCode Therapeutics
Summary company analytics:TransCode Therapeutics Inc. - RNAZ
TransCode Therapeutics (RNAZ) operates in the preclinical development stage of RNA therapeutics, relying on investment capital in the absence of stable operating income. The quarterly dynamics of net income per share digitize the rate of profit change relative to the previous period, allowing investors to use this chart to assess the cash burn rate or the market reaction to corporate events given the lack of commercial products.
Analysis of competing companies
Tempus AI Inc (TEM) - Year-over-year earnings per share growth for the last twelve months|Earnings per share growth in annualized terms for the last twelve months Qiagen NV (QGEN)|IONS (Ionis Pharma) - Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last 12 months RGEN (Repligen Inc.)|Quarterly EPS earnings growth RNA|CRSP - Earnings per share growth in annualized terms for the last twelve months|GeneDx - Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per one share growth for the last 12 months RARE|BEAM: Year-over-year net earnings per share growth for the last 12 months|Sarepta Corp - Year-over-year earnings per share growth rate for the last twelve months|TWST: Quarterly EPS earnings growth|10xgenomics.com - Year-over-year earnings per one share growth for the last 12 months|NTLA (Intellia Therapeutics, Inc.) - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Stoke Therapeutics Inc STOK|Year-over-year earnings per share growth for the last twelve months BioLife Corp (BLFS)|WVE (Wave Pharma) - Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth MAZE (Maze Therapeutics Inc)|Quarterly EPS earnings growth sionnatx.com SION|PRME - Year-over-year earnings per share growth for the last twelve months|Year-over-year net earnings per share trend for the last twelve months TSHA|QURE: Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months MeiraGTx Corp (MGTX)|Year-over-year net earnings per share growth for the last 12 months RGNX|Quarterly EPS earnings growth solidbio.com|Year-over-year net earnings per share growth for the last 12 months OCGN (Ocugen)|Year-over-year earnings per share growth rate for the last twelve months PACB|Quarterly EPS earnings growth BNTC (Benitec)|Year-over-year net earnings per share change for the last twelve months Design Corp (DSGN)|Rocket Pharmaceuticals - Quarterly EPS earnings growth|4dmoleculartherapeutics.com (FDMT) - Year-over-year net earnings per share growth for the last 12 months|lexeotx.com (LXEO) - Year-over-year earnings per share growth for the last twelve months|KRRO - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months Editas|SLN: Year-over-year earnings per one share growth for the last 12 months|Year-over-year earnings per share growth for the last twelve months ProQR Therapeutics N.V. (PRQR)|codexis.com - Year-over-year earnings per share growth for the last 12 months|Quarterly EPS earnings growth SGMO (Sangamo Therapeutics, Inc.)|Quarterly EPS earnings growth Nautilus Biotechnology, Inc. NAUT|MGX: Year-over-year net earnings per share growth for the last 12 months|Year-over-year net earnings per share trend for the last twelve months DTIL|GBIO: Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last 12 months BOLD|Year-over-year earnings per share growth for the last twelve months Exicure Inc.|Year-over-year earnings per share growth for the last 12 months IMNN (Celsion Corporation)|Quarterly EPS earnings growth PHIO|Quarterly EPS earnings growth mustangbio.com (MBIO)|Bionano Genomics - Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per share growth rate for the last twelve months APDN (adnas.com)|BLUE - Year-over-year earnings per share growth for the last twelve months|Year-over-year earnings per one share growth for the last 12 months IPA (ImmunoPrecise Antibodies)|OMGA: Quarterly EPS earnings growth|Singular Genomics Corp (OMIC) - Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last twelve months Regulus Therapeutics|Year-over-year earnings per share growth for the last 12 months SYRS (syros.com)|Year-over-year earnings per share growth for the last twelve months Telesis Bio (TBIO)|Year-over-year net earnings per share change for the last twelve months TRACON Pharmaceuticals Inc.|Quarterly EPS earnings growth UBX (Unity Bio)
